^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MultiTAA T cell therapy

    i
    Other names: MultiTAA T cell therapy, MultiTAA-specific T cells
    Associations

    News

    Trials
    Company:
    Baylor College of Medicine, Marker Therap
    Drug class:
    MAGE-A4 inhibitor, NY ESO 1 inhibitor, Survivin inhibitor, PRAME inhibitor, SSX2 inhibitor, Tumor-associated antigen inhibitor
    Related drugs:
    Associations

    News

    Trials
    16d
    STELLA: Administration of Donor MultiTAA-Specific T Cells for ALL (clinicaltrials.gov)
    P1, N=40, Completed, Baylor College of Medicine | Active, not recruiting --> Completed
    Trial completion
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • MME (Membrane Metalloendopeptidase)
    |
    MultiTAA T cell therapy
    5ms
    Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (clinicaltrials.gov)
    P1, N=44, Recruiting, Baylor College of Medicine | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • WT1 (WT1 Transcription Factor) • CD33 (CD33 Molecule) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    MultiTAA T cell therapy
    5ms
    TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Baylor College of Medicine | Trial completion date: May 2024 --> May 2025
    Trial completion date
    |
    MultiTAA T cell therapy
    over1year
    Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (clinicaltrials.gov)
    P1, N=44, Recruiting, Baylor College of Medicine | Trial primary completion date: Apr 2023 --> Apr 2024
    Trial primary completion date
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • WT1 (WT1 Transcription Factor) • CD33 (CD33 Molecule) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    MultiTAA T cell therapy
    over2years
    Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. (PubMed, Ther Adv Med Oncol)
    This was associated with in vivo T-cell expansion, persistence, and antigen spreading. Future directions of this approach may include additional strategies to enhance the therapeutic benefit of multiTAA T cells in patients with BC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BIRC5 (Baculoviral IAP repeat containing 5) • CTAG1B (Cancer/testis antigen 1B) • MAGEA4 (Melanoma antigen family A, 4) • PRAME (Preferentially Expressed Antigen In Melanoma)
    |
    ER positive + PGR positive • PGR positive • EGFR positive • BIRC5 expression
    |
    MultiTAA T cell therapy
    over2years
    Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (clinicaltrials.gov)
    P1, N=44, Recruiting, Baylor College of Medicine | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Apr 2022 --> Apr 2023
    Trial completion date • Trial primary completion date
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • WT1 (WT1 Transcription Factor) • CD33 (CD33 Molecule)
    |
    MultiTAA T cell therapy